Heterocyclic sodium/proton exchange inhibitors and method

US6887870B1 · kind B1 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Saleem Ahmad · Wall, US
• Shung C. Wu · Princeton, US
• Steven Victor O'Neil · East Lyme, US
• Khehyong Ngu · Pennington, US
• Karnail Atwal · Newtown, US
• David S. Weinstein · Plainsboro, US

Key dates

• Filing date: Sep 25, 2000
• Grant date: May 3, 2005
• Expiry date: Nov 14, 2020

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Heterocyclic are provided which are sodium/proton exchange (NHE) inhibitors which have the structure wherein n is 1 to 5; X is N or C—R5 wherein R5 is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; Z is a heteroaryl gorup, R1, R2, R3 and R4 are as defined herein, and where X is N. R1 is preferably aryl or heteroaryl, and are useful as antianginal and cardioprotective agents. In addition, a method is provided for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia employing the above heterocyclic derivatives.